TrialPloS one2025

A phase I/II study of adoptive immunotherapy using donor liver graft-derived NK cell-enriched immune cells to prevent severe infection after liver transplantation.

Masahiro Ohira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.